Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir

Weerawat ManosuthiSomnuek SungkanuparphKiat RuxrungthamWisit PrasithsirikulChatiya AthichathanabadiWoraphot TantisiriwatChureeratana BowonwatanuwongNopphanath ChumpathatAchara ChaovavanichThailand Ministry of Public HealthMahidol UniversityThe HIV Netherlands Australia Thailand Research CollaborationSrinakharinwirot UniversityChonburi Regional Hospital2018-07-122018-07-122008-01-01Journal of Acquired Immune Deficiency Syndromes. Vol.47, No.1 (2008), 127-129152541352-s2.0-39049117418https://repository.li.mahidol.ac.th/handle/123456789/19384Mahidol UniversityImmunology and MicrobiologyPlasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavirLetterSCOPUS10.1097/QAI.0b013e318157b0da